clinical trial · NCT04396236
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company·phase3·terminated·n = 851
MigraineLasmiditanPlacebo
brief summary
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
started
Jun 15, 2020
primary completion
Nov 12, 2025
completion
Nov 12, 2025
last updated
Mar 10, 2026
official title
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol